Based on the evidence and consensus, Italian experts recommended that anti-IL-1 therapy was considered relatively safe and effective in treating refractory AOSD patients, especially the systemic subtype patients, as either the first line or a subsequent line of biological treatment [129]. The gene discussed is IL1B; the disease is adult-onset Still disease.